EGFR inhibitors prolong survival in non-small-cell lung cancer
A new meta-analysis shows their superiority over chemotherapy
2nd September 2019
Adjunct targeted molecular therapy may prolong disease-free survival in patients with resected non-small cell lung cancer harbouring epidermal growth factor receptor mutations, a meta-analysis suggests.